Analytics

Standardization is needed in CAR-T cell therapy development due to its inherent complexity.

The author introduces a practical approach to determining the best estimate of probability for passing multiple stage dissolution tests.

Effective cleaning and disinfection along with contamination controls are imperative when operating and utilizing a cleanroom.

Thermo Fisher Scientific’s new Gibco CTS Xenon Electroporation System aims to provide easier scale up for cell therapies, from clinical development to commercial manufacturing.

Under the two-year task order, ATCC will continue to support the DCEG MEAS program in receiving, processing, storing, analyzing, and distributing clinical specimens from different cancer types.

Any improper validation of methods is likely to result in regulatory agency deficiencies that range in degree of severity.

ProteoGenix’s new XtenCHO Transient Expression can achieve up to ten times higher yields than market-leading CHO systems.

The importance of getting buy-in from regulatory authorities early in the development process is critical in order to establish meaningful specifications.

Researchers at McGill University have made advancements with a novel method for growing synthetic bone tissue.

Bio-Rad has launched a range of antibodies specifically for daratumumab that inhibit the binding of the drug to the target antigen, CD38, which allows for highly specific bioanalysis and drug monitoring.

Thermo Fisher and Symphogen have extended their collaboration involving improved data workflow, which supports the discovery and development of new cancer treatments.

Scientists can work to overcome the challenges associated with protein characterization through empowering technologies.

Borrowing is good, but invention is best.

The acquisition and analysis of MS data can be made more efficient with the integration of modern software tools.

The automation of analytical workflows generates higher volumes of data that also require advanced technologies to manage.

An overview of technologies aiming to improve laboratory processes from the past year.

A new portfolio of chromatography and mass spectrometry consumables launched by Thermo Fisher Scientific is designed to meet higher performance requirements while remaining economical.

Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.

Automated analytical workflows require advanced technologies to manage the higher volume of data output.

The multispecific analysis of biologics is a complex task that requires appropriate strategies.

Personnel need to be trained in various analytical skill sets for biologic drug substance testing.

Ensuring reliable analytical methods and bioassays requires a well-thought-out strategy for evaluating method validity and systems suitability.

IonSense’s DART-MS technology offers rapid drug analysis without the need for sample preparation.

Texcell North America’s new lab facility in Frederick, Md., will expand the CRO’s capabilities in R&D cell culture, viral clearance studies, and viral safety testing.

PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.

In their collaboration, Bristol Myers Squibb and Prellis Biologics aim to generate human antibody libraries for select targets to enable drug discovery.

After a previously announced merger, Protagen Protein Services, BioAnalytix, and GeneWerk have formed a new CRO under the name ProtaGene.

Fujifilm Diosynth Biotechnologies' 89,000 square-foot expansion of its BioProcess Innovation Center in Research Triangle Park, N.C., will double its capacity to support process characterization.

The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.

Particle analysis provides assurances of the quality and performance of the final dosage form in pharmaceutical development.